Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator
March 30, 2023 07:00 ET
|
Smart Immune
Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator PARIS, France, 30 March, 2023 – Smart Immune SAS, a...
Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator
March 30, 2023 04:24 ET
|
Smart Immune
Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator PARIS, France, 30 March, 2023 – Smart Immune SAS, a...
Smart Immune is selected for the first cohort of the French Tech Health20 program
March 27, 2023 07:32 ET
|
Smart Immune
Smart Immune is selected for the first cohort of the French Tech Health20 program This unique program has selected 20 French start-ups that offer disruptive healthcare innovations PARIS, France,...
Smart Immune appoints world-class Clinical Advisory Board
November 21, 2022 07:00 ET
|
Smart Immune
Smart Immune appoints world-class Clinical Advisory Board PARIS, France, November 21, 2022 – Smart Immune SAS, a clinical-stage biotechnology company developing ProTcell™, a pioneering new approach...
Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers
October 13, 2022 07:00 ET
|
Smart Immune
Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers First trial...
Smart Immune Bolsters Management Team with Medical and Technical Appointments
September 13, 2022 07:00 ET
|
Smart Immune
Smart Immune Bolsters Management Team with Medical and Technical Appointments Dr Frederic Lehmann, MD, appointed Chief Medical Officer and Dr Pierre Heimendinger, PharmD, appointed Chief Technical...
Smart Immune appoints world-leading experts to its Scientific Advisory Board
July 28, 2022 07:00 ET
|
Smart Immune
Smart Immune appoints world-leading expertsto its Scientific Advisory Board PARIS, France, July 28, 2022 – Smart Immune SAS, a clinical-stage biotechnology company developing ProTcell™, a...
Marcel R. M. van den Brink, MD, PhD Appointed Chairman of Smart Immune’s Scientific Advisory Board
July 06, 2022 07:25 ET
|
Smart Immune
Marcel R. M. van den Brink, MD, PhD Appointed Chairman of Smart Immune’s Scientific Advisory Board PARIS, France, July 6, 2022 – Smart Immune SAS, a clinical-stage biotechnology...
Smart Immune Announces Oral Presentation of Cell-Fate Plasticity Data of its T-cell Progenitor-Based Therapy Platform (ProTcell™) at ASGCT 2022
May 20, 2022 06:00 ET
|
Smart Immune
PARIS, May 20, 2022 (GLOBE NEWSWIRE) -- Smart Immune, a clinical-stage biotechnology company focused on saving and improving lives by delivering to patients a new generation of thymus-empowered T...
Smart Immune Announces Research Collaboration with Memorial Sloan Kettering Cancer Center (MSK) to Expedite Development of a Next Generation CAR-T Through its Long Lasting, Exhaustion-Free CAR ProTcell™ Platform
December 09, 2021 05:30 ET
|
Smart Immune
PARIS, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Smart Immune SAS, a clinical stage T-cell medicine company utilizing its proprietary ex-vivo biomimetic “thymus-in-a-dish” technology to develop T-cell...